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Abstract
Background: Patients with long-term intestinal failure are usually treated by means of home parenteral nutrition
(HPN) where they administer their nutritional formulation intravenously via a central venous access device (mostly a
catheter). This implies that such patients are exposed to a lifelong risk of developing Staphylococcus aureus
bacteremia (SAB). SAB poses a threat to both catheter and patient survival and may lead to frequent hospitalization
and a permanent loss of vascular access. In other clinical settings, S. aureus carriage eradication has been proven
effective in the prevention of S. aureus infections. Unfortunately, there is a complete lack of evidence in HPN
support on the most effective and safe S. aureus decolonization strategy in S. aureus carriers. We hypothesized that
long-term S. aureus decolonization in HPN patients can only be effective if it is aimed at the whole body (nasal and
extra-nasal) and is given chronically or repeatedly on indication. Besides this, we believe that S. aureus carriage
among caregivers, who are in close contact with the patient, are of great importance in the S. aureus transmission
routes.
Methods/design: The CARRIER trial is a randomized, open-label, multicenter clinical trial in Dutch and Danish
hospitals that treat patients on HPN. A total of 138 adult HPN patients carrying S. aureus will be randomly assigned
to a search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment, or a continuous suppression
(CS) strategy, a repeated chronic topical antibiotic treatment. The primary outcome measure is the proportion of
patients in whom S. aureus is totally eradicated during a 1-year period. Secondary outcomes are time to successful
eradication, long-term antimicrobial resistance, adverse events, patient compliance, incidence of (S. aureus)
infections, catheter removals, mortality rates, S. aureus transmission routes, quality of life, and health care costs.
Discussion: The CARRIER trial is designed to identify the most safe and effective long-term S. aureus carriage
decolonization strategy in HPN patients. This will eventually lead to a better understanding of long-term S. aureus
decolonization treatments in general. The results of this study will have a great impact on our daily clinical practice,
which eventually may result in less S. aureus-related infections.
Trial registration: ClinicalTrials.gov; NCT03173053. Registered on 1 June 2017.
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Background
Intestinal failure and home parenteral nutrition
The number of patients with intestinal failure in the
Netherlands has increased exponentially over the past
decade, from approximately 100 to 400 patients (Fig. 1).
These patients depend on life-long home parenteral
(intravenous) nutrition (HPN). HPN is a complex and
time-consuming treatment focused around training pa-
tients to use their venous catheter and infusion pump at
home. With the use of such venous access come fre-
quent life-threatening complications, such as
catheter-related bloodstream infections (CRBSIs). The
reported incidence of CRBSIs in expert centers ranges
from 0.38 to 4.58 episodes per 1000 catheter days and
accounts for approximately 70% of all HPN-related hos-
pital admissions [1, 2]. These complications are a threat
to both the catheter and patient survival and may lead
to permanent loss of vascular access. Because most HPN
patients are well-trained to perform complex aseptic
techniques to manage their catheters, further improve-
ment of these techniques will likely have no significant
impact on infection prevention.
Staphylococcus aureus infections and carriage
Staphylococcus aureus related to catheter exit-site, tun-
nel infections, and bacteremia (SAB) may all lead to
complicated infections resulting in catheter loss [1]. On
top of this, SABs easily result in secondary metastatic in-
fectious foci leading to high morbidity and mortality
rates of 20 to 30% [3–5]. In addition to the psychological
impact on patients, healthcare-associated costs are sub-
stantial; around $30.000 per infection [5].
By estimation, the prevalence of nasal S. aureus car-
riage in HPN patients is comparable to hemodialysis pa-
tients, over 30% [6]. Nasal S. aureus carriage is a
well-defined risk factor for subsequent S. aureus infec-
tions, and vice versa. Finally, more than 80% of health
care-associated S. aureus infections are endogenous of
origin [7, 8]. Studies show that the risk of developing S.
aureus infections is 11.5 times higher among colonized
hemodialysis patients compared with uncolonized pa-
tients [9]. In addition, approximately 19% of dialysis pa-
tients who are S. aureus carriers develop a S. aureus
infection each year [9]. Infection prevention is a key
strategy to maintain venous access and to avoid
hospitalization. As such, S. aureus carriage eradication is
instrumental for infection prevention. Besides this, evi-
dence is mounting that extra-nasal S. aureus
colonization is more common than previously believed.
The usual decolonization strategies with only mupirocin
nasal ointment are probably insufficient because
extra-nasal body regions remain colonized with S. aur-
eus. Finally, the role of S. aureus transmission to the
HPN patient by a close partner or caregiver is unclear.
Of note, the setting of HPN support poses a unique add-
itional challenge here, since the caregiver is a critical fac-
tor in S. aureus carriage and transmission because the
management of the patient’s venous catheter is often
performed by the partner on a continuous basis.
Rationale for S. aureus decolonization in HPN patients
The above demonstrates that evidence-based recom-
mendations for S. aureus decolonization are needed,
specifically for HPN patients and their caregivers. Unfor-
tunately, current guidelines do not provide such recom-
mendations; patients are currently treated—mostly
based on “expert opinion”—with oral antibiotics, topical
antibiotics, or nothing at all. This results in large treat-
ment variations between the hospitals and even between
clinicians.
We hypothesized that long-term S. aureus
decolonization in HPN patients can only be effective if
the decolonization treatment is aimed at the whole body
(nasal and extra-nasal) and is given chronically or
Fig. 1 Incidence of patients on home parenteral nutrition (HPN) from 1997 to 2017 in the Radboudumc Nijmegen, The Netherlands. The
exponential increase of HPN patients is attributed to a higher patient survival, multimorbidity, and the increase of complex surgical procedures
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repeatedly on indication. The aim of the CARRIER trial
is to improve patient care by reliably identifying the
most effective and safe long-term S. aureus carriage
decolonization strategy in HPN patients. Ultimately this
will lead to less antimicrobial resistance, less catheter re-
movals, and lower mortality rates. The CARRIER trial
protocol was written in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT). The SPIRIT checklist has been included
as Additional file 1.
Methods
Design
The CARRIER trial is a multicenter, randomized con-
trolled, open label, superiority trial in adult HPN pa-
tients carrying S. aureus. It aims to investigate the most
effective and safe long-term S. aureus carriage
decolonization strategy. The trial will recruit 138 pa-
tients that will be randomized to either a “search and
destroy” (SD) group or a “continuous suppression” (CS)
group (Figs. 2 and 3). The study design mirrors the
real-life setting with respect to costs and effects.
Setting
The setting of this study is the outpatient clinic of the
Endocrinology and Metabolism department of one
Dutch academic hospital and the Gastroenterology and
Hepatology departments of one Dutch and two Danish
academic hospitals. The expected duration of this study
is 3 years (6 months of preparation time and 2.5 years
for enrollment and follow-up). The Danish HPN popula-
tion is very similar to the Dutch HPN population in
terms of infection rates, methicillin-resistant S. aureus
(MRSA) prevalence, provided healthcare, healthcare sys-
tem, and (benign) diseases leading to intestinal failure.
Trial population
All adult patients with intestinal failure on HPN will be
screened for S. aureus carriage. With the expectation
that at least 30% of the HPN patients are S. aureus car-
riers, approximately 700 patients will need to be
screened. In case S. aureus carriage is confirmed, the pa-
tient will be screened for further eligibility and asked to
enroll in the trial.
Inclusion criteria
In order to be eligible to participate in this study, a pa-
tient must meet all of the following criteria:
 Patient is fully able to understand the nature of the
proposed intervention.
 Patient is diagnosed with intestinal failure and
receives HPN.
 Written informed consent is provided by the patient
before entering the trial.
 Age ≥ 18 years.
 Estimated life expectancy ≥ 1 year.
 Patient colonized with S. aureus (nasal and/or extra-
nasal).
Exclusion criteria
A patient who meets any of the following criteria will be
excluded from participation:
 Cannot be expected to comply with the trial plan
(substance abuse, mental condition).
 Pregnant or breastfeeding women.
 Continuous exposure to MRSA (e.g., pig farmer).
 Allergy for both chlorhexidine and/or betadine.
 No options for any of the study drugs (systemic
and/or topical antibiotics) due to resistance, allergies
and/or interacting co-medication.
Fig. 2 Study design of the CARRIER trial. Seven hundred parenteral nutrition patients will be screened for S. aureus colonization. A total of 138 S.
aureus carriers will be included, of which 69 patients will be randomized to the search and destroy group and 69 patients to the continuous
suppression group
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 Active S. aureus infection.
 Currently on treatment with antibiotics active
against S. aureus.
 Decolonization (including mupirocin) treatment in
the previous 2 months.
 The presence of an irremovable nasal foreign body.
 Aspartate transaminase (AST) and alanine
transaminase (ALT) levels more than five times the
upper limit of normal or liver failure.
Study intervention
Prior to the start of the trial, HPN patients have been
screened for S. aureus carriage with swabs of the
nose, throat, rectum, exit-site catheter, and body re-
gions on indication (e.g. stoma, wound, skin lesion).
Subsequently, enrolled patients will visit the regular
outpatient clinic appointments every 6 months, in ac-
cordance with current guidelines [10].
After randomization, patients will be allocated to one
of the following two treatment strategies:
 Search and destroy (SD) strategy focuses on the
quick and short, systemic antibiotic eradication of S.
aureus (Fig. 4). Patients will receive treatment with
mupirocin nasal ointment, a chlorhexidine
oropharyngeal rinse and body wash, and two
systemic antibiotics for one week, according to the
Dutch MRSA guideline [10]. Hygienic measures
consist of wearing clean clothing every day and
frequent change of towels and bed clothes during
Fig. 3 Schedule of enrollment, interventions, and assessments. Schedule of enrollment, interventions, and assessments according to the SPIRIT
2013 guidelines. NGS next-generation sequencing, EQ5D-5 L EuroQol 5 Dimensions, 5 levels, TSQM treatment satisfaction questionnaire
measurement, iMCQ iMTA Medical cost questionnaire, M month(s). *In case of S. aureus eradication failure
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treatment. Combination therapy is indicated
because of improved effectiveness and a decreased
chance of developing resistance. After one cycle
of treatment, a set of body swabs (nose, throat,
rectum, exit-site catheter, and body regions on in-
dication (e.g. stoma, wound, skin lesion) will be
taken weekly for 3 weeks to confirm total eradica-
tion. In case of persistent S. aureus carriage, pa-
tients will be treated again. Patients will not
receive more than three treatment cycles per
round. A successful treatment is defined as three
consecutive negative sets of surveillance cultures
obtained at least 48 h after completion of treat-
ment and distributed over a period of at least
14 days. Treatment failure is defined when a pa-
tient is still a S. aureus carrier after three
treatment cycles. Relapse of S. aureus carriage will
be subsequently monitored at the standard new
swab rounds, every 3 months. In case of relapse,
patients will be treated again as well.
 Continuous suppression (CS) strategy focuses on
the continuous, topical eradication of S. aureus
(Fig. 5). Whether or not patients are carriers during
the year, they will receive mupirocin nasal ointment,
an oropharyngeal chlorhexidine rinse, and body
wash for extra-nasal body regions every month for 5
days. The same hygienic measures as in the SD strat-
egy group will be applied. Standard swabs of the
nose, throat, rectum, exit-site catheter, and other
body regions on indication will be taken every
3 months to monitor full body eradication.
Fig. 4 Search and destroy group strategy. Flow chart of the search and destroy group treatment strategy
Fig. 5 Continuous suppression group strategy. Flow chart of the continuous suppression group treatment strategy
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Outcome measures
 Primary outcome
Proportion of patients in whom S. aureus is totally
eradicated during a 1-year time period.
Total eradication is defined as 100% of all swabs
(nose, throat, rectum, exit-site catheter, and body re-
gions on indication) being negative for S. aureus per
measured time point.
 Secondary outcomes
Secondary outcomes are listed in Table 1.
Procedures, participants, and analyses
Recruitment and screening
The subjects of this study will be identified from local
HPN databases of the different study sites. Patients will
be selected by the attending physicians and local nurse
practitioners. The local investigator will provide infor-
mation about the study by phone and will subsequently
send information material, including the Informed Con-
sent Agreement, to the patient’s home address. Informed
consent will be obtained before the start of any
study-specific procedures (e.g., randomization). Data will
be saved in a documentation system based on electronic
Case Report Forms (eCRFs; CastorEDC 2017.9). Castor-
EDC is compliant with ICH-GCP and all the regulations
required by FDA 21CFR Part 11 for electronic data
management.
Randomization
Randomization will be performed centrally by the princi-
pal investigators using an online randomization module
(CASTOR EDC 2017.9) in a 1:1 ratio to either a SD
group or a CS group (Figs. 2 and 3). Randomization will
be stratified by country to balance differences in national
treatment guidelines and different antimicrobial suscep-
tibility patterns. Variable block randomization consisting
of two, three, or four marbles will be used to provide
treatment allocation in equal proportions. We consid-
ered a blinded design, but the treatment strategy proto-
cols of both groups differ to such an extent that this
precludes adequate blinding. Besides this, an unblinded
(more pragmatic) design fits best with the current ideas
about the external validity of cost-effectiveness studies.
Baseline examination
At the start of the trial, patient characteristics (from
existing electronic patient system, medical history, and/
or by physical examination), results of earlier obtained
culture swabs, and/or blood results will be collected on
the eCRF by the investigator.
Choice of antibiotic drug(s)
Patients will be treated according to the respective mar-
keting authorizations and national MRSA guidelines as
previously mentioned (Table 2). The choice of antibiotic
drugs depends on known allergies, expected decreased
absorption in the case of short bowel, and susceptibility
Table 1 Secondary outcome measures
Secondary outcome measure Data collection instrument or method
Incidence of S. aureus infections (S)AE forms every 3 months
Overall incidence of infections (S)AE forms every 3 months
Mortality Data from electronic patient file
Long-term antimicrobial resistance Culture results every 6 months and NGS
Number of catheter removals Data from electronic patient file
Time to first catheter-related infection (S)AE forms every 3 months and data from electronic patient file
Successful S. aureus eradication per body site Culture results
Relapse rate of S. aureus carriage Culture results and NGS
Transmission routes Caregivers culture results and NGS
S. aureus transmission routes NGS
Adverse events (S)AE forms every 3 months
Predictors for infections and treatment failure or success Binominal regression analysis
Patient compliance Medication files, counting pills, trial-specific medication diary, modified Morisky Medication
adherence questionnaire
Generic health related quality of life EuroQol 5 dimension, 5 levels questionnaire (EQ5D-5 L)
Treatment satisfaction TSQM vII questionnaire
Healthcare related costs iMCQ questionnaire
iMCQ iMTA Medical Consumption Questionnaire, NGS next-generation sequencing, (S)AE (serious) adverse event, TSQM Treatment Satisfaction Questionnaire
for Medication
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patterns of the S. aureus isolates. If during the course of
the study the treating physician or consulted specialist
infectious diseases feels that a particular antibiotic drug
is clearly indicated or contra-indicated in a patient, the
choice of the antibiotic drug may be changed at his/her
discretion.
Caregivers
In case of treatment failure, a patient’s caregiver (often
the patient’s partner) will be asked to participate in the
trial to investigate transmission routes from the care-
giver to the patient. Presence of a caregiver is not
mandatory for the patient’s participation. Caregivers will
not be randomized nor treated. Next-generation sequen-
cing (NGS) will be used to determine the type of S. aur-
eus strains and to compare them with the strains
retrieved from caregivers and/or previous S. aureus
isolates.
Bacteriological methods
Identification of S. aureus and storage of positive cul-
tures To screen patients for S. aureus carriage, flocked
swabs with moisture (Eswab) will be used. To ensure
high quality of this procedure, training for the nurses
and patients’ caregivers and an instruction brochure will
be provided prior to the start of the study. After collec-
tion, the swab will be placed in 100 μl of saline and cen-
trifuged. Real-time PCR (polymerase chain reaction) and
conventional cultures will be used for the detection of S.
aureus isolates. Cultures will be performed after broth
enrichment, which improves the performance of
chromogenic solid media for the detection of S. aureus
in clinical samples (sensitivity of 95–97%). This is ac-
cording to the national MRSA detection guidelines and
will be the same for all the participating centers [11].
For perineum swabs, CAN agar plates will be used. This
is a selective microbiological medium for S. aureus,
which inhibits Gram-negative bacteria during culture.
All S. aureus isolates will be stored at − 80 °C in
glycerol-containing liquid media for the duration of
1 year after the end of the study.
Next-generation sequencing NGS, performed with
Illumina NextSeq (Illumina, San Diego, CA, USA), will
be used in a subgroup of subjects (for example, in case
of relapse or occurrence of active S. aureus infection). S.
aureus strains will be distinguished by comparing single
nucleotide polymorphisms (SNPs) in the core genome
and by relating these SNPs to the genealogical tree of S.
aureus. A cut-off point of 30 different SNPs will be used
to classify S. aureus strains as distinct [12].
Follow-up
Patients will be followed for 1 year. At months 6 and 12,
swabs will be obtained at the outpatient clinic and ques-
tionnaires regarding adverse events (AEs) will be col-
lected. In between outpatient visits, at 3 and 9 months,
swabs will be sent to the laboratory and patients will be
interviewed via telephone to assess adverse events and
treatment satisfaction with a validated questionnaire
(TSQM vII). At inclusion and 6 and 12 months, generic
health-related quality of life and health care costs will be
measured with questionnaires as well (EQ-5D-5 L,
iMCQ). Discontinuation of study treatment by patients
will be recorded, including the reason for discontinu-
ation. If possible, a final visit procedure (collecting swabs
1 year after inclusion) will be performed.
Patient compliance
At months 6 and 12, patient compliance will be moni-
tored by medication files, a trial-specific medication
diary (on paper or digital via medication application
MedApp), and specific questions regarding medication
adherence. In addition, all patients will have a
study-specific list with information about their S. aureus
Table 2 Systemic combination therapy for eradication of MRSA carriage in complicated carriage according to the Dutch MRSA
guideline [10]
Dutch MRSA guideline Antibiotic 1 Antibiotic 2
Recommended Sulfamethoxazole/Trimethoprim 960 mg twice daily
or
Doxycycline 200 mg once daily
Rifampicin 600 mg twice daily
Alternativeɑ Clindamycin 600 mg thrice daily
or
Clarithromycin (or another macrolide) 500 mg twice daily
or
Ciprofloxacin (or another quinolone) 750 mg twice daily
or
Fusidic acid 500 mg thrice daily
or
Linezolid 600 mg twice daily
Fusidic acid 500 mg thrice daily
All treatments are prescribed preferably by means of tablets or capsules. The dosages in this table are the recommended dosages for an adult patient of about
70 kg. Combination therapy will be used because of better effectiveness and a decreased chance of developing resistance
ɑAlternative options should only be used when there is a contraindication (e.g., in vitro resistance, intolerance) for the recommended options
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screening and treatment protocol. We chose this method
for measuring adherence because it is pragmatic and re-
liable, without influencing the daily practice too much.
Data management
All data will be handled confidentially and, where neces-
sary, anonymized. The investigator will record all data in
an eCRF. All files will be encrypted by a password only
known by the investigators. Originals of laboratory or
other tests related to the study will be kept on file at the
study site. This study will be performed in accordance
with the legal laws formulated in the Dutch “Wet
Bescherming Persoonsgegevens”.
Analysis
Sample size and power calculation
Hardly any literature is available regarding long-term ef-
ficacy of the CS group on total S. aureus carriage eradi-
cation. Even when articles describe similar eradication
strategies as the CS group, endpoints vary from only
local, nasal S. aureus eradication to S. aureus infections.
Consequently, total body site (de)colonization has not
been described thoroughly. Based on a few studies with
quite similar eradication strategies, it is, however, pos-
sible to make an assumption about the long-term effi-
cacy [10, 13–16]. The eradication rate of the SD strategy
group is expected to be 77% and for the CS strategy
group 55% over 1 year. Based on the settings binary out-
come (carriage yes/no), superiority trial, power (1 − β) of
80% and a significance level (α) of 5%, a total of 138 pa-
tients (2 × 69) are required to detect a significant in-
crease from 55 to 77%.
Statistical analysis
The primary analysis will be based on the intention-to-treat
principle.
Primary study parameter(s) The primary endpoint
(proportion of S. aureus eradication during a 1-year time
period, using logistic mixed models) will be expressed in
terms of odds ratios and 95% confidence intervals (CI).
If the 95% CI does not contain value 1, we can conclude
that either of the strategies is significantly different from
the other.
We choose a logistic mixed-effect model because it is
a linear model that fits best for this longitudinal study
using repeated dichotomous measures. In addition, lo-
gistic mixed-effects models have a better distinguishing
ability. It is expected that this results in an even greater
power than the more simplistic area under the curve
model that was used for the power analysis.
Secondary study parameter(s) Continuous data such as
patient characteristics (age, sex, venous access, CRBSIs)
will be presented as means ± standard deviation and in
case of skewed distributions as medians and range. Di-
chotomous outcomes will be summarized as percent-
ages (N events/N total). Parameters will be compared
between both groups by the Student’s t-test, Wilcoxon
rank sum test, Chi2-test or Fischer exact test depend-
ing on the type of outcome and distribution. A
two-tailed p value < 0.05 is considered statistically sig-
nificant. No corrections for multiple tests are applied.
Known predictors (such as socio-economic status, pet
ownership, location of S. aureus carriage, S. aureus car-
riage by caregiver, and active skin disease) for infections
and treatment failure/success will be analyzed using a
logistic and/or linear regression model.
Cost-effectiveness analysis The cost-effectiveness gain
related to the proposed eradication strategies lies in the
comparison with having no strategy at all (doing noth-
ing) and the prevention of infections. “Doing nothing” is
not included in this trial because it is considered uneth-
ical as we clearly expect no eradication at all. The num-
ber of infections is expected to be low in this trial and
the positive effects of prevention of infection do extend
the time horizon of this trial. Therefore, the prospect-
ively gathered data in this trial will be combined with lit-
erature into a Markov model in order to estimate the
incremental cost-effectiveness (ICER) from a health care
perspective over a time horizon of 5 years. The model is
needed to estimate the infection rate in a doing-nothing
strategy, to relate infections to quality of life losses, and
to extrapolate the trial data. During the trial the quality
of life of patients will be assessed by the EQ-5D-5 L at
baseline and 6 and 12 months and the result (Dutch tar-
iff ) will be used to derive a QALY estimate for each pa-
tient according to the trapezium rule. The cost analysis
consists of two main parts. First, at the patient level, vol-
umes of care related to the HPN care and infections will
be measured by means of the iMTA Medical Consump-
tion Questionnaire (iMCQ). In addition, the medication
use will be derived from the electronic patient records.
Loss of productivity due to illness or recovery will not
be included in the analyses because, on estimation, only
5% of the HPN patients perform paid (or unpaid) labor.
The second part of the cost analysis consists of deter-
mining the cost prices for each volume of consumption.
The standard cost prices from the “Dutch Guidelines for
Cost Analyses” and https://www.medicijnkosten.nl/ will
be used. In the end, volumes of care will be multiplied
by the cost prices for each volume of care to calculate
costs. Two incremental cost-utility ratio’s (ICURs),
expressed as costs per QALY gained, will be calculated—
one for each strategy compared to doing nothing.
Model-based cost-effectiveness analyses will be carried
out using probabilistic sensitivity analysis, by Monte
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Carlo simulation, to take all uncertainties surrounding
the input parameters into account. The costs will be in-
cluded across a gamma distribution, the probabilities
and utilities with beta distributions, which is according
to the guidelines of the ISPOR. The results of the 5000
simulations will be plotted in cost-effectiveness planes
and in willingness to pay curves.
Budget impact analysis A budget impact analysis (BIA)
will be performed according to the ISPOR principles of
Good Practice for BIA. This BIA allows prediction of the
financial consequences related to the adaption and im-
plementation of one of the eradication strategies, in
order to determine the affordability of the intervention.
Data will be used that reflect the size and characteristics
of the HPN population in the Netherlands together with
the results of this trial (effect sizes, resource use, etc).
When relevant, budget impact analyses are generated as
a series of scenario analyses.
Quality and safety
In general, this study aims to restrict the physical and
mental burdens for the subject as much as possible. The
physical risks that are introduced by this study to the
participants are believed to be minimal. The risk derived
from collecting the culture swabs is negligible if per-
formed by well trained physicians, nurse practitioners,
and/or the patient’s own caregiver. For this, we will pro-
vide an information brochure and give instructions dur-
ing the outpatient clinic visit. Next to this, the systemic
antibiotics as prescribed in the SD group have the po-
tential risks of causing side effects, certain toxicities and
allergies, or intolerance. These potential risks, however,
are all well known because the antibiotics that are pre-
scribed are part of the routine care and are prescribed
following the current national guidelines. During the
study sufficient medical health assistance (nurse practi-
tioners, attending physician or principle investigator)
will be present at all times in the hospital and reachable
by phone to cope with unexpected events. Serious ad-
verse events will be reported through a web portal to the
central committee on research involving human subjects
(in Dutch: Centrale Commissie Mensgebonden Onder-
zoek) and the accredited institutional review board
(https://www.toetsingonline.nl/). The remaining events
are recorded in an electronic database and reviewed an-
nually by an independent monitor.
Monitoring
During the trial, two independent monitors (one in the
Netherlands and one in Denmark) will visit the sites
yearly to check the completeness of patient records, the
accuracy of entries on the CRFs, the adherence to the
protocol and to Good Clinical Practice (GCP), the
progress of enrollment, and also to ensure that trial de-
vices are being stored, dispensed, and accounted for ac-
cording to specifications.
Discussion
This trial will provide guidance for further policy devel-
opment and implementation of (long-term) S. aureus
decolonization protocols and other novel infection/
transmission preventive strategies. HPN patients, and
likely other chronic patient groups such as hemodialysis
patients, will benefit from an evidence-based effective
and safe long-term S. aureus decolonization protocol.
Ultimately such a protocol will lower S. aureus infec-
tions and reduce subsequent hospitalizations, catheter
removals, mortality, antimicrobial resistance, and costs.
We believe that with this project we can gain essential
knowledge that fills a significant gap in our current un-
derstanding of (long-term) S. aureus decolonization
treatments. As such, the CARRIER trial will prove the
efficacy of a long-term S. aureus decolonization strategy
in HPN patients for the first time. The study will give
insight into other important outcome measures such as
antimicrobial resistance, S. aureus transmission, patient
compliance and—as a completely new feature—the role
of the caregiver and his/her carrier status.
During the trial, antibiotic drugs will be used accord-
ing to the national MRSA eradication guidelines [10].
These drugs are also used in clinical practice for eradica-
tion of methicillin-sensitive S. aureus (MSSA) since
there is no separate guideline for MSSA eradication. The
MRSA guideline based their advice on studies that were
not restricted to the eradication of MRSA only, but in-
cluded studies evaluating MSSA eradication as well.
There is no evidence that any of the treatment options
included in the MRSA guideline have a more favorable
risk:benefit ratio in the HPN population. Allowance of
different treatment regimens that are included in the
MRSA guideline enables us to include patients with cer-
tain allergies or potential interacting co-medication as
well. This is in line with current clinical practice and en-
ables us to include enough patients to answer the re-
search question.
From the patients’ perspective, the trial will have many
advantages as well. Implementation of the trial results
might lead to less morbidity (less hospitalizations and
complications such as S. aureus infections and catheter
removals) and eventually a lower mortality. In addition,
we think that the results of this study will most likely
have an impact on daily clinical practice, since our aim
is to implement the findings in the (inter)national guide-
lines on chronic intestinal failure in adults.
Strengths of this trial include its multicenter, random-
ized controlled design in different international centers,
which will increase the (international) generalizability of
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the study. Besides this, barely any studies have investi-
gated effective long-term S. aureus eradication strategies.
The outcomes include mostly objective measures to de-
termine successful S. aureus eradication: the results of
bacterial cultures and the additional whole-genome se-
quencing in some cases. The questionnaires used for the
subjective patient-reported outcomes (e.g., impact on
overall quality of life (QOL), treatment satisfaction, and
health care related costs) are well-accepted, reliable, and
mostly validated (TSQM vII, EQ-5D-5 L and iMCQ).
Lastly, the burden for patients is expected to be minimal
since the feasible treatment protocol chosen has limited
impact on daily life.
In summary, the findings of this study will help to de-
termine what the most effective and safe long-term S.
aureus decolonization strategy in HPN patients is. The
trial will determine the relative contribution of two dif-
ferent decolonization strategies on successful eradica-
tion, reduction of catheter-related bloodstream
infections (CRBSIs), and eventually a lower mortality.
Trial status
Currently, the trial is ongoing and patient recruitment
started at the end of 2017. The estimated end date will
be in Q4 of 2019.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist. (DOC 122 kb)
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